Phase 2 RCT in 80 patients with higher-risk prostate cancer having an HDR brachytherapy boost: ultrahypofractionated whole-pelvis radiotherapy was non-inferior to conventional fractionation for 1-year EPIC bowel function (90.6 vs 88.4).
RCTn = 80
Mendez et al. Ultrahypofractionated Versus Conventionally Fractionated Whole-pelvis Radiotherapy in Prostate Cancer: A Randomized Clinical Trial